Market News Video
MNV MNV 10 Bargains You Can Buy Cheaper Than Insiders Did
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

See How Ligand Pharmaceuticals Ranks Among Analysts' Top Picks With Strong Buyback Activity
Monday, October 18, 1:16 PM ET, by Market News Video Staff

A study of analyst recommendations at the major brokerages shows that Ligand Pharmaceuticals Inc (LGND) ...

Implied VIOO Analyst Target Price: $240
Monday, November 1, 8:42 AM ET, by Market News Video Staff

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, ...

Notable Monday Option Activity: LGND, VSTO, RAPT
Monday, November 15, 3:33 PM ET, by Market News Video Staff

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume ...

Notable Wednesday Option Activity: FLOW, MRVL, LGND
Wednesday, December 1, 3:37 PM ET, by Market News Video Staff

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy ...

Analysts Forecast 26% Gains Ahead For The Holdings of PJP
Thursday, December 2, 8:51 AM ET, by Market News Video Staff

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, ...

Ligand Pharmaceuticals Becomes Oversold (LGND)

By Market News Video Staff, Thursday, September 22, 6:02 PM ET
Play Video: Learn About The RSI

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Email EnvelopeFree Email Alerts By Stock:
Get Dividend Alerts
Get SEC Filing Alerts

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.

In trading on Thursday, shares of Ligand Pharmaceuticals Inc (NASDAQ:LGND) entered into oversold territory, hitting an RSI reading of 29.4, after changing hands as low as $80.81 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 32.9. A bullish investor could look at LGND's 29.4 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of LGND shares:

Ligand Pharmaceuticals Inc 1 Year Performance Chart

Looking at the chart above, LGND's low point in its 52 week range is $72.57 per share, with $169.98 as the 52 week high point — that compares with a last trade of $81.50. Find out what 9 other oversold stocks you need to know about »

Free Report: Top 7%+ Dividends (paid monthly)

This Article's Word Cloud:   About   Buffett   Dividends   Find   Free   Index   Know   LGND   Legendary   Ligand   Looking   Oversold   Pharmaceuticals   Relative   Report   Should   Start   Stocks   Strength   Thursday   Warren   about   above   advises   after   analysis   begin   below   bullish   called   changing   chart   compares   comparison   fearful   greedy   investor   look   others   oversold   point   raquo   reading   share   shares   stock   that   week   when   with
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV MNV Chart Zero Stock Market Game Stock Market Definitions

Ligand Pharmaceuticals Becomes Oversold (LGND) | Market News Video | Copyright © 2008 - 2022, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.